Understanding heterogeneity and Improving the Precision of Prostate Cancer Clinical Outcomes in the Modern Era
Abstract
Currently, when a man develops metastatic prostate cancer and is commencing testosterone suppression, a decision needs to be made as to whether to add in docetaxel, a chemotherapy agent, or an agent that blocks the activity of the androgen receptor even further (abiraterone, enzalutamide, apalutalide, darolutamide). All of these drugs have been shown to prolong the survival of men in this setting. But not all men respond to these treatments, and we need to develop more therapies in an expeditious manner. Another major problem facing both physicians and men with metastatic hormone-sensitive prostate cancer is whether a specific therapy will work well for their individual needs and is a major unmet clinical need. Another unmet need is understanding the variability in response in men with hormone sensitive prostate cancer. In this Data Science Award (DSA), our team proposes to understand the factors that impacts a patient’s survival. Clinical Applications: By identifying the prognostic factors of OS, they can assist in identifying subgroups of men with particularly good or poor prognoses for whom therapy can be subsequently tailored. These factors can be incorporated into management of patients. We have assembled a team of internationally recognized medical oncologists, urologists, radiation oncologists, biostatisticians and clinical trialists in prostate cancer who have led the development and validation of models as well as clinical trials. We are uniquely positioned to leverage existing resources and conduct the proposed analysis that addresses the overarching challenges to optimize treatments of men with metastatic prostate cancer over this 3-year DOD DSA grant and will combine our institutional resources as leverage to ensure success. Successful development of prognostic models for survival and identification of patients who fail very quickly while on therapy will have short- and long-term impact for the prioritization of novel treatments, as well as the design and expeditious conduct (optimal sample size and duration of trial) and analysis of trials, and would speed the development of new treatments that will lead to faster access to effective care for men with advanced prostate cancer.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Jan 04, 2024
- Source ID
- HT94252310394
Entities
People
- Christopher Sweeney
Organizations
- United States Army
- University of Adelaide